NeoGenomics (FRA:NG9) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NG9 NeoGenomics Inc FRA:NG9
73 GF Score
Price €13.70
GF Value €14.32
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics SpecialCharges?

Special Charges only applies to banks.

FRA:NG9
73GF Score
NeoGenomics Inc FRA:NG9
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NeoGenomics (FRA:NG9) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of €13.70 is trading 4.4% below its estimated GF Value™ of €14.32. GuruFocus considers NeoGenomics to be Fairly Valued.

Key valuation signals for FRA:NG9:

  • SpecialCharges:
  • GF Value™: €14.32 vs. price of €13.70 (4.4% below fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the FRA:NG9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NeoGenomics Business Description

Other Exchanges NEO:USANEO:Mexico
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
73GF Score

Get the complete analysis for FRA:NG9

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.70
Price
€14.32
GF Value